Logo image of ILMN

ILLUMINA INC (ILMN) Stock Overview

USA - NASDAQ:ILMN - US4523271090 - Common Stock

95.03 USD
-2.77 (-2.83%)
Last: 10/29/2025, 6:27:54 PM
95.9 USD
+0.87 (+0.92%)
After Hours: 10/29/2025, 6:27:54 PM

ILMN Key Statistics, Chart & Performance

Key Statistics
Market Cap14.61B
Revenue(TTM)4.28B
Net Income(TTM)1.26B
Shares153.70M
Float153.39M
52 Week High156.66
52 Week Low68.7
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)4.16
PE22.84
Fwd PE19.18
Earnings (Next)10-30 2025-10-30/amc
IPO2000-06-28
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences


ILMN short term performance overview.The bars show the price performance of ILMN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 15 20

ILMN long term performance overview.The bars show the price performance of ILMN in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of ILMN is 95.03 USD. In the past month the price decreased by -7.07%. In the past year, price decreased by -36.55%.

ILLUMINA INC / ILMN Daily stock chart

ILMN Latest News, Press Relases and Analysis

ILMN Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 24.92 210.82B
DHR DANAHER CORP 27.76 153.24B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28 143.51 46.81B
A AGILENT TECHNOLOGIES INC 26.28 40.60B
IQV IQVIA HOLDINGS INC 18.73 37.03B
MTD METTLER-TOLEDO INTERNATIONAL 34.09 28.72B
WAT WATERS CORP 28.08 20.44B
WST WEST PHARMACEUTICAL SERVICES 40.29 20.48B
MEDP MEDPACE HOLDINGS INC 40.88 16.42B
TEM TEMPUS AI INC N/A 15.43B
ICLR ICON PLC 12.58 12.91B
RVTY REVVITY INC 19.9 11.06B

About ILMN

Company Profile

ILMN logo image Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.

Company Info

ILLUMINA INC

5200 Illumina Way

San Diego CALIFORNIA 92122 US

CEO: Francis A. deSouza

Employees: 9000

ILMN Company Website

ILMN Investor Relations

Phone: 18582024500

ILLUMINA INC / ILMN FAQ

Can you describe the business of ILLUMINA INC?

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.


What is the current price of ILMN stock?

The current stock price of ILMN is 95.03 USD. The price decreased by -2.83% in the last trading session.


Does ILLUMINA INC pay dividends?

ILMN does not pay a dividend.


What is the ChartMill rating of ILLUMINA INC stock?

ILMN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Which stock exchange lists ILMN stock?

ILMN stock is listed on the Nasdaq exchange.


What is the ownership structure of ILLUMINA INC (ILMN)?

You can find the ownership structure of ILLUMINA INC (ILMN) on the Ownership tab.


ILMN Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ILMN. When comparing the yearly performance of all stocks, ILMN is a bad performer in the overall market: 87.52% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ILMN Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to ILMN. ILMN scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ILMN Financial Highlights

Over the last trailing twelve months ILMN reported a non-GAAP Earnings per Share(EPS) of 4.16. The EPS increased by 352.17% compared to the year before.


Industry RankSector Rank
PM (TTM) 29.37%
ROA 20.67%
ROE 55.71%
Debt/Equity 0.66
Chartmill High Growth Momentum
EPS Q2Q%230.56%
Sales Q2Q%-4.77%
EPS 1Y (TTM)352.17%
Revenue 1Y (TTM)-3.27%

ILMN Forecast & Estimates

29 analysts have analysed ILMN and the average price target is 113.85 USD. This implies a price increase of 19.8% is expected in the next year compared to the current price of 95.03.

For the next year, analysts expect an EPS growth of 87.51% and a revenue growth -1.43% for ILMN


Analysts
Analysts71.72
Price Target113.85 (19.8%)
EPS Next Y87.51%
Revenue Next Year-1.43%

ILMN Ownership

Ownership
Inst Owners102.96%
Ins Owners0.18%
Short Float %4.35%
Short Ratio4.36